Naunyn-Schmiedeberg's archives of pharmacology最新文献_第10页

Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1. 黄芪甲苷IV-PESV通过增强ZDHHC1介导的GSDMD蛋白棕榈酰化促进焦亡。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-16 DOI: 10.1007/s00210-025-04122-x

Xujun You, Honghan Li, Qixin Li, Qing Zhang, Yiguo Cao, Wei Fu, Bin Wang

{"title":"Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1.","authors":"Xujun You, Honghan Li, Qixin Li, Qing Zhang, Yiguo Cao, Wei Fu, Bin Wang","doi":"10.1007/s00210-025-04122-x","DOIUrl":"10.1007/s00210-025-04122-x","url":null,"abstract":"Prostate cancer (PCa) is an epithelial malignancy affecting the prostate gland. Astragaloside IV combined with polypeptide extract from scorpion venom (PESV) has been reported to inhibit the growth of PCa. This study aimed to investigate the mechanisms by which this combination mitigates the progression of PCa. Bioinformatic analysis was utilized to investigate the correlation between zinc finger DHHC-type containing 1 (ZDHHC1) expression and PCa progression. The extent of pyroptosis in PCa cells was assessed by measuring cell viability, IL-1β and IL-18 secretion, LDH release, and HMGB1 content. PCa mouse models were constructed by subcutaneous injection of DU145 or PC-3 cells into nude mice, with subsequent monitoring of tumor weight and volume. ZDHHC1 expression was significantly lower in PCa patient tissues, which correlated with a poor prognosis. ZDHHC1 overexpression inhibited PC-3 and DU145 cell viability and increased IL-1β, IL-18, LDH, and HMGB1 levels in cell supernatants. Notably, the pyroptosis inhibitor LDC7559 partially reversed these effects. Co-IP assay demonstrated an interaction between ZDHHC1 and GSDMD. ZDHHC1 overexpression significantly enhanced GSDMD palmitoylation-mediated membrane translocation and pyroptosis; however, this effect was partially reversed by the palmitoylation inhibitor 2-BP. The combination of Astragaloside IV and PESV promoted GSDMD membrane translocation and pyroptosis in PCa cells, with ZDHHC1 knockdown partially reversing the effects of Astragaloside IV-PESV. Furthermore, treatment with Astragaloside IV-PESV significantly inhibited tumor tissue growth in tumor-bearing nude mouse models. Astragaloside IV-PESV enhances palmitoylation-mediated membrane translocation of GSDMD-N by upregulating ZDHHC1 expression, thereby facilitating pyroptosis in PCa cells and attenuating PCa progression.","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13925-13939"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MST1/2 DKO abates salvianolic acid B's therapeutic effect on CCl₄-induced liver injury mice. MST1/2 DKO可减弱丹酚酸B对ccl4致小鼠肝损伤的治疗作用。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-12 DOI: 10.1007/s00210-025-04140-9

Yanyan Xu, Yu Zhang, Mengru Yang, Changfeng Xue, Yuqi Dang, Yan Yang, YongfangGong

{"title":"MST1/2 DKO abates salvianolic acid B's therapeutic effect on CCl4-induced liver injury mice.","authors":"Yanyan Xu, Yu Zhang, Mengru Yang, Changfeng Xue, Yuqi Dang, Yan Yang, YongfangGong","doi":"10.1007/s00210-025-04140-9","DOIUrl":"10.1007/s00210-025-04140-9","url":null,"abstract":"MST1 and MST2 (MST1/2) are core kinases of the Hippo/YAP signaling pathway in mammals and play key roles in various liver diseases. Deep molecular profiling has shown that the Hippo/YAP pathway interacts synergistically with TGF-β1/Smad2 signaling. Salvianolic acid B (SAB) is an ingredient extracted from Salvia miltiorrhiza that can be used to treat liver diseases. Previous studies have confirmed that SAB hold commendable efficacy against liver injury by inhibition of inflammatory response and Smad2C/2L phosphorylation. However, scientific evidence involving how mutations in the Hippo/YAP pathway are related to the hepatoprotective function of SAB in MST1/2 double knockout (MST1/2 DKO) mice remains vague. Nowadays, the MST1-/- MST2fl/fl Alb-Cre mice were generated to establish a CCl4-induced liver injury model to investigate the potential effects of MST1/2 gene knockout on inflammatory reactions and pSmad2C/pSmad2L signal transduction with the intervention of SAB. As it turns out, genotype identification and western blot assays confirmed that we have successfully obtained MST1-/- MST2fl/fl Alb-Cre mice. General observation, HE staining, and biochemical assays promulgated that genetic deletion of MST1/2 could diminish SAB's hepatoprotective effect on liver injury by promoting the phosphorylation of smad2C/2L and boosting the expression of the inflammatory factors IL- 6 and TNF-α. In summary, these results suggest that MST1/2 play a key role in mediating SAB's effects on liver injury.","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13731-13743"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyroptosis and its role in intestinal ischemia-reperfusion injury: a potential therapeutic target. 焦亡及其在肠缺血再灌注损伤中的作用：一个潜在的治疗靶点。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-15 DOI: 10.1007/s00210-025-04261-1

Wenping Xu, Lang Wang, Ruili Chen, Yi Liu, Wendong Chen

引用次数: 0

Correction: The potential liver injury induced by metronidazole-provoked disturbance of gut microbiota: modulatory effect of turmeric supplementation. 更正：甲硝唑引起的肠道菌群紊乱引起的潜在肝损伤：姜黄补充剂的调节作用。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 DOI: 10.1007/s00210-025-04433-z

Abdulaziz Q Ali, Deema Kamal Sabir, Amal F Dawood, Mohammed Abu-Rashed, Abdulrahman Hasari, Faiz Gharqan, Salem Alnefaie, Lama E Mohiddin, Maya M Tatry, Dana A Albadan, Mohanad M Alyami, Mohammed F Almutairi, Lamiaa M Shawky

引用次数: 0

Editorial Expression of Concern: HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. 编辑关注：HP-β-CD-PLGA纳米颗粒提高葛根素的渗透和生物利用度，增强对大鼠脑缺血再灌注损伤的治疗作用。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 DOI: 10.1007/s00210-025-04437-9

Hai-Quan Tao, Qingfeng Meng, Ming-Hui Li, Hui Yu, Mei-Fang Liu, Dan Du, Shou-Li Sun, Hai-Cheng Yang, Yan-Ming Wang, Wei Ye, Li-Zhuang Yang, Da-Ling Zhu, Chuan-Lu Jiang, Hai-Sheng Peng

引用次数: 0

Linezolid administration to lactating Wistar rats affects the health of their offspring. 给哺乳期Wistar大鼠施用利奈唑胺影响其后代的健康。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-12 DOI: 10.1007/s00210-025-04060-8

Aya G Hamouda, Entsar R Abd-Allah, Aya A Mahmoud

{"title":"Linezolid administration to lactating Wistar rats affects the health of their offspring.","authors":"Aya G Hamouda, Entsar R Abd-Allah, Aya A Mahmoud","doi":"10.1007/s00210-025-04060-8","DOIUrl":"10.1007/s00210-025-04060-8","url":null,"abstract":"Lactational exposure to antibacterial medications may affect the normal development of newborns during this crucial stage and later in adult life. Linezolid (LNZ) is an oxazolidinone antibacterial drug that is effective against drug-resistant Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis. Although it is relatively toxic, there is insufficient data about LNZ use during lactation. This study aimed to elucidate the impact of linezolid administration during lactation on Wistar rats' offspring. Eighteen lactating Wistar female rats were separated into three groups (n = 6): control, therapeutic, and low dose groups. The therapeutic dose group received 61.66 mg/kg of LNZ (equivalent to the human dose), while the low dose group received 15.41 mg/kg of LNZ (1/4 of the human therapeutic dose) by gavage twice daily. All lactating dams and their offspring died four days after receiving a therapeutic dose. In the low dose group, LNZ significantly reduced the body weight of lactating females and their pups. The liver tissue of the pups showed a considerable increase in malondialdehyde levels, along with a decrease in the catalase, glutathione, and superoxide dismutase activities accompanied by moderate histological alterations like congestion, and infiltration, and DNA fragmentation as indicated by comet assay. Microscopic examination of renal tissue revealed glomeruli deterioration, cellular infiltration, and intratubular protein deposits. In conclusion, this study highlights the potential risks linezolid may pose to infants during postpartum. Therefore, there is a need for preweaning monitoring and caution should be taken during breastfeeding.","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13695-13705"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative pharmacokinetics and bioequivalence of 145-mg fenofibrate formulations in healthy Korean participants. 145毫克非诺贝特制剂在健康韩国参与者中的比较药代动力学和生物等效性。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-30 DOI: 10.1007/s00210-025-04086-y

Sujong Lee, Byungwook Kim, SeungHwan Lee, Seung-Hyun Kang, Kyung-Sang Yu

{"title":"Comparative pharmacokinetics and bioequivalence of 145-mg fenofibrate formulations in healthy Korean participants.","authors":"Sujong Lee, Byungwook Kim, SeungHwan Lee, Seung-Hyun Kang, Kyung-Sang Yu","doi":"10.1007/s00210-025-04086-y","DOIUrl":"10.1007/s00210-025-04086-y","url":null,"abstract":"Fenofibrate is a serum lipid-modifying agent that is commonly used to treat dyslipidemia. This study aimed to compare the pharmacokinetics (PKs) and establish bioequivalence of two 145-mg fenofibrate formulations, AD-104 (test) and TRICOR® (reference). This randomized, open-label, two-sequence, two-period crossover study was conducted in healthy Korean participants. Forty participants were enrolled and received either the test or reference formulation during each period, with a 14-day washout between doses. Blood samples were collected pre-dose and up to 72 h post-dose. PK parameters were assessed using non-compartmental analysis with Phoenix WinNonlin®. Bioequivalence was determined if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of the maximum plasma concentration (Cmax) and the area under the concentration-time curve from time zero to the last measurable plasma concentration (AUClast) were within the bioequivalence limits of 0.80 to 1.25. Thirty-eight participants completed the study and were included in the PK analysis. The GMR and 90% CIs for the Cmax and AUClast of the test compared to the reference formulation were 0.8643 (0.8283-0.9019) and 0.9930 (0.9631-1.0239), respectively, both within the bioequivalence limits. No serious adverse events were reported during the study. This study demonstrates that the test formulation is bioequivalent to the reference formulation in healthy Korean participants. Both formulations were safe and well-tolerated; therefore, AD-104 is expected to benefit Korean patients with dyslipidemia. Clinical Research Information Service No. is as follows: KCT0009332 (April 12, 2024).","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"14461-14466"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Exploring the bioactive ingredients of three traditional Chinese medicine formulas against age-related hearing loss through network pharmacology and experimental validation. 更正：通过网络药理学和实验验证，探索三种抗老年性听力损失中药方剂的生物活性成分。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 DOI: 10.1007/s00210-025-04307-4

Wenying Shi, Qi Zhao, Hongwei Gao, Yaxin Yang, Zhiyong Tan, Na Li, Hongjie Wang, Yonghua Ji, You Zhou

引用次数: 0

Lipoic acid as a protective agent against lipopolysaccharide and other natural toxins: a comprehensive review. 硫辛酸作为抗脂多糖和其他天然毒素的保护剂：综述。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-04-14 DOI: 10.1007/s00210-025-04123-w

Seyedeh Farzaneh Omidkhoda, Fatemeh Rajabian, Hossein Hosseinzadeh

{"title":"Lipoic acid as a protective agent against lipopolysaccharide and other natural toxins: a comprehensive review.","authors":"Seyedeh Farzaneh Omidkhoda, Fatemeh Rajabian, Hossein Hosseinzadeh","doi":"10.1007/s00210-025-04123-w","DOIUrl":"10.1007/s00210-025-04123-w","url":null,"abstract":"Alpha-lipoic acid, also known as lipoate or lipoic acid (LA), is naturally present in the mitochondria of cells, where it functions as a cofactor for dehydrogenase enzyme complexes. It has also been reported that LA is a potent antioxidant. Not only does it scavenge free radicals directly, but it can also regenerate other essential cellular antioxidants. LA exhibits various anti-inflammatory effects and offers protection to mitochondria. Numerous studies have assessed the potential protective effects of LA against natural toxins, including lipopolysaccharides, galactosamine, mycotoxins, snake venoms, and toxins derived from cyanobacteria and plants. In general, the results of these studies indicate that LA can be effective in mitigating various toxicities, primarily due to the previously mentioned capabilities. Furthermore, novel mechanisms have been proposed for LA against specific toxins, for example, direct inactivation of secretory phospholipase A2 in some snake venoms or enhancement of p-glycoprotein activity to prevent saxitoxin entry into the neuronal cells. However, the gaps in the available data from most animal experiments conducted to date have resulted in insufficient evidence to justify further clinical evaluations of the effects of LA on human poisoning cases. Consequently, more extensive research is required to address these gaps and fully realize the therapeutic potential of this valuable substance.","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"12811-12829"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolomics as a tool for understanding and treating triple-negative breast cancer. 代谢组学作为了解和治疗三阴性乳腺癌的工具。

IF 3.1 4区医学

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-10-01 Epub Date: 2025-05-02 DOI: 10.1007/s00210-025-04234-4

Gyas Khan, Md Sadique Hussain, Sarfaraz Ahmad, Nawazish Alam, Md Sajid Ali, Prawez Alam

{"title":"Metabolomics as a tool for understanding and treating triple-negative breast cancer.","authors":"Gyas Khan, Md Sadique Hussain, Sarfaraz Ahmad, Nawazish Alam, Md Sajid Ali, Prawez Alam","doi":"10.1007/s00210-025-04234-4","DOIUrl":"10.1007/s00210-025-04234-4","url":null,"abstract":"Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous variant of breast cancer distinguished by a lack of targeted therapies, posing significant challenges in diagnosis and treatment. Metabolomics, the comprehensive study of small compounds in biological systems, has been identified as an instrument for revealing the metabolic underpinnings of TNBC. This review highlights recent advancements in metabolomic approaches, such as mass spectrometry and nuclear magnetic resonance, which have identified metabolic vulnerabilities, resistance mechanisms, and potential therapeutic targets. Key findings include alterations in fatty acid, amino acid, and glutathione metabolism, along with hypoxia-driven metabolic reprogramming that contributes to disease progression. The combination of metabolomics with multi-omics techniques, supported by advanced computational methods such as machine learning, offers a pathway to overcome challenges in data standardization and biological complexity. Emerging strategies, including the use of artificial intelligence and multidimensional omics approaches, are paving the way for personalized medicine by enabling the discovery of novel biomarkers and targeted therapies. Despite these advances, significant hurdles remain, including the need for robust data standardization, validation of findings in diverse patient cohorts, and seamless integration with clinical workflows. By addressing these challenges, metabolomics has the potential to revolutionize TNBC management, offering tools for early detection, precision therapy, and improved patient outcomes. This review underscores the importance of interdisciplinary collaboration to translate metabolomic insights into actionable clinical applications.","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"13351-13370"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0